Union Pacific Railroad is the principal operating company of Union Pacific Corporation (UNP). One of America's most recognized companies, Union Pacific Railroad connects 23 states in the western two-thirds of the country by rail, providing a critical link in the global supply chain. This article discusses the reasons to be bullish on Union Pacific after strong results in July 24, 2014.
Union Pacific has made a strong comeback after the financial crisis and the company�� fundamentals have improved significantly over the last five years. Union Pacific�� diluted earnings per share have increased from $3.74 in 2009 to $9.42 in 2013.
During the same period, the company�� dividend per share has surged to $2.96 from $1.08. Amidst an increase in dividends, the company�� operating cash flow has also increased to $6.8 billion in 2013 from $3.2 billion in 2009.
Union Pacific has also been successful in reducing the company�� debt to capital from 37% in 2009 to 31% in 2013. From a shareholder return perspective, the return on equity has surged to 21.4 in 2013 from 11.8 in 2009.
Hot Sliver Stocks To Invest In Right Now: Hancock Holding Company(HBHC)
Hancock Holding Company, a financial holding company, provides various banking and financial services in south Mississippi, Louisiana, South Alabama, and Florida. The company accepts various deposit products that include non-interest bearing demand deposits, NOW account deposits, money market deposits, savings deposits, and time deposits. Its loan portfolio comprises provision of commercial, consumer, commercial leasing, and real estate loans to consumers and small and middle market businesses. Hancock also offers various trust services that include operating as an executor, administrator, or guardian in administering estates; provision of investment custodial services for individuals, businesses, and charitable and religious organizations, as well as investment management services on an agency basis; and trustee services for pension plans, profit sharing plans, corporate and municipal bond issues, living trusts, life insurance trusts, and various other types of trusts cre ated for individuals, businesses, and charitable and religious organizations. In addition, it provides consumer financing services; owns, manages, and maintains real property; offers general insurance agency services; holds investment securities; markets credit life insurance; and engages in discount investment brokerage services, as well as owns approximately 3,700 acres of timber land in Hancock County, Mississippi. The company operates 182 banking and financial services offices and 161 automated teller machines. Hancock Holding Company was founded in 1899 and is headquartered in Gulfport, Mississippi.
Advisors' Opinion:- [By Dividends4Life]
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
CTBI is trading at a premium to all four valuations above. The stock is trading at a 53.5% premium to its calculated fair value of $29.43. CTBI did not earn any Stars in this section.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
CTBI earned one Star in this section for 1.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. The company has paid a cash dividend to shareholders every year since 1988 and has increased its dividend payments for 33 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
1. NPV MMA Diff.
2. Years to > MMA
The negative NPV MMA Diff. means that on a NPV basis the dividend earnings from an investment in CTBI would be less than a similar amount invested in MMA earning a 20-year average rate of 3.41%. If CTBI grows its dividend at 1.5% per year, it will never equal a MMA yielding an estimated 20-year average rate of 3.41%.
Memberships and Peers: CTBI is, a member of the Broad Dividend Achieve - [By Eric Volkman]
Hancock Holding (NASDAQ: HBHC ) is resolutely sticking to its longtime dividend policy. Matching the same common stock payout it's distributed since September 2006, the financial services concern has declared a distribution of $0.24 per share. This is to be paid on September 16 to shareholders of record as of September 5.
Hot Railroad Companies To Watch For 2014: IN Media Corp (IMDC)
IN Media Corporation, formerly Tres Estrellas Enterprises, Inc., incorporated on March 5, 2007, is a development-stage company. The Company focuses on providing integrated Internet protocol television (IPTV) services for platform providers for any device from large screen televisions to handheld mobile phones. It provides a combination of hardware, software, manufacturing and content services for platform providers to either complete their offerings or provide an all-in-one solution. On October 16, 2009, the Company executed an agreement between In-Media Corporation (In-Media) and the Company, subsequent to which In-Media was merged into the Company.
The Company�� partnerships with platform providers, such as Comcast, AT&T, DirecTV, provide an installed base of customers, as well as allowing platform providers to be the billing and service interface to customers. The Company is focusing on its first implementation in China through its Chinese distributor, which will include provision of set top boxes (STB)-related system support, reference platforms and technology, and access to over 4,000 titles of Hollywood and Bollywood movies.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks IN Media Corp (OTCMKTS: IMDC), Epazz Inc (OTCMKTS: EPAZ) and Polaris International Holdings (OTCMKTS: PIHN) have been busy developing new devices/products or making acquisitions. Moreover, at least two of these small cap stocks have been the subject of paid promotions or investor relations types of activities. Keeping that in mind, will new devices/products or acquisitions help these small caps along with their investors or traders? Here is a closer look:
Hot Railroad Companies To Watch For 2014: First Trust Dow Jones Internet Index Fund (FDN)
First Trust Dow Jones Internet Index Fund (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Dow Jones Internet Composite Index (the Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index represents companies that generate the majority of their revenues via the Internet. The Index aims to represent 80% of the float-adjusted Internet equity universe. The Index contains two sub-indexes, the Dow Jones Internet Commerce Index and the Dow Jones Internet Services Index. For its stock to be eligible for the universe, a company must generate at least 50% of annual sales/revenues from the Internet, and be included in the Dow Jones U.S. Index. The Fund�� investment advisor is First Trust Advisors L.P. Advisors' Opinion:- [By MONEYMORNING.COM]
That's where the First Trust Dow Jones Internet Index (NYSE Arca: FDN) comes in.
Besides Facebook, which is its largest holding, FDN also owns Amazon.com (Nasdaq: AMZN) and both classes of Google Inc. (Nasdaq: GOOGL), which has voting rights, and GOOG, which does not.
Hot Railroad Companies To Watch For 2014: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.
In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.
Advisors' Opinion:- [By James Fink]
And lastly I'll go into healthcare, which is kind of a growth cyclical type name. It's partially defensive, partially growth. I think the more growth-oriented section of healthcare would be biotech, and right now, a very promising biotech stock is Enanta Pharmaceuticals. That's a NASDAQ stock; ticker symbol (ENTA).
- [By George Budwell]
Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV ) , Enanta Pharmaceuticals (NASDAQ: ENTA ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�
- [By Sean Williams]
The next big thing in treating hepatitis-C
The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi.
Hot Railroad Companies To Watch For 2014: Griffin Land & Nurseries Inc.(GRIF)
Griffin Land & Nurseries, Inc., together with its subsidiaries, engages in real estate and landscape nursery businesses in the United States. The company?s real estate business consists of the ownership, construction, leasing, and management of commercial and industrial properties, as well as the development of residential subdivisions on real estate owned by it in Connecticut, Massachusetts, and Pennsylvania. Its landscape nursery business comprises the growing of containerized plants for sale principally to independent retail garden centers, rewholesalers, mass merchandisers, home centers, and landscape contractors. Griffin Land & Nurseries, Inc. was founded in 1970 and is based in New York City, New York.
Advisors' Opinion:- [By Dividends4Life]
Memberships and Peers: ADM is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers��Index and a Dividend Champion. The company's peer group includes: Bunge Limited (BG) with a 1.6% yield, Ingredion Incorporated (INGR) with a 2.4% yield and Griffin Land & Nurseries Inc. (GRIF) with a 0.7% yield.
Hot Railroad Companies To Watch For 2014: Prosensa Holding NV (RNA)
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.
Advisors' Opinion:- [By Leo Sun]
However, these three biotech stocks -- Amarin (NASDAQ: AMRN ) , Dendreon (NASDAQ: DNDN ) , Prosensa (NASDAQ: RNA ) -- don't fit that category at all. Read on to understand why these dogs of the sector should never be mistaken as underdogs.
- [By Brian Orelli]
Ironically, phase 3 data from Sarepta's direct competitor -- GlaxoSmithKline (NYSE: GSK ) and Prosensa's (NASDAQ: RNA ) drisapersen -- that's due in the fourth quarter could help the FDA answer the question about whether dystrophin is an acceptable surrogate endpoint. If increases in dystrophin correlate with clinical outcomes, it would support approving eteplirsen with less data. It's not clear to me whether Glaxo and Prosensa would have to share that correlation with the FDA -- the clinical phase 3 data should be sufficient for approval -- and if it does make those calculations whether the FDA could legally use it to support the approval of another drug since NDA data is proprietary while under patent.
- [By Bryan Murphy]
Anybody who knows at least something about Prosensa Holding NV (NASDAQ:RNA) will at least know the stock turned into a disaster a few weeks ago, plunging from a close of $24.00 on September 19th to a close of $7.14 on September 20th, thanks to the failure of its MS drug drisapersen, which was jointly developed with GlaxoSmithKline plc (NYSE:GSK). Such is the life of a company with only one drug anywhere close to being approved; drisapersen was in Phase 3 trials - RNA shares could have just as easily gained 70% rather than lost 70% had the drug worked.
No comments:
Post a Comment